Shelley B. Thunen
Known title: Chief Financial OfficerCIK: 0001297491
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds. Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.
Transaction History
| AEON | ▲ Buy | Grant | 222,684 | $0 | 6/17/2026 | View on chart |
| RXST | ▲ Buy | Option Exercise | 7,792 | $34K | 4/14/2025 | View on chart |
| RXST | ▲ Buy | Option Exercise | 15,000 | $240K | 10/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 9,521 | $464K | 10/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 278 | $14K | 10/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 5,201 | $249K | 10/1/2024 | View on chart |
| AEON | ▲ Buy | Grant | 36,021 | $0 | 8/31/2024 | View on chart |
| RXST | ▲ Buy | Option Exercise | 16,505 | $72K | 7/15/2024 | View on chart |
| RXST | ▲ Buy | Option Exercise | 10,000 | $156K | 7/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 1,803 | $107K | 7/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 8,146 | $476K | 7/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 6,599 | $386K | 7/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 1,854 | $110K | 7/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 9,620 | $507K | 5/1/2024 | View on chart |
| RXST | ▲ Buy | Option Exercise | 10,247 | $160K | 5/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 380 | $20K | 5/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 543 | $28K | 4/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 200 | $10K | 4/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 8,857 | $441K | 4/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 800 | $40K | 4/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 8,938 | $445K | 4/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 662 | $33K | 4/1/2024 | View on chart |
| RXST | ▲ Buy | Option Exercise | 10,000 | $156K | 3/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 6,361 | $359K | 3/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 2,473 | $141K | 3/1/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 1,166 | $64K | 3/1/2024 | View on chart |
| RXST | ▲ Buy | Option Exercise | 15,875 | $237K | 2/6/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 15,875 | $754K | 2/6/2024 | View on chart |
| RXST | ▲ Buy | Option Exercise | 6,900 | $30K | 2/5/2024 | View on chart |
| RXST | ▲ Buy | Option Exercise | 9,125 | $136K | 2/5/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 9,125 | $429K | 2/5/2024 | View on chart |
| RXST | ▲ Buy | Option Exercise | 31,772 | $479K | 1/26/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 31,772 | $1.5M | 1/26/2024 | View on chart |
| RXST | ▲ Buy | Option Exercise | 4,500 | $20K | 1/26/2024 | View on chart |
| RXST | ▲ Buy | Option Exercise | 10,000 | $156K | 1/2/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 4,519 | $175K | 1/2/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 5,481 | $217K | 1/2/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 10,000 | $393K | 12/15/2023 | View on chart |
| RXST | ▼ Sell | Open Market | 10,000 | $393K | 12/15/2023 | View on chart |
| RXST | ▼ Sell | Open Market | 20,000 | $787K | 12/15/2023 | View on chart |
| RXST | ▲ Buy | Option Exercise | 20,000 | $312K | 12/15/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
AEON Biopharma Shares FDA Feedback on ABP-450 Biosimilar Plan
AEON Biopharma received feedback from the FDA following a Type 2b meeting, which helps clarify the development path for its ABP-450 biosimilar candidate. This regulatory update provides specific guidance on the next steps for the company's pipeline. The stock recently appeared on lists of active healthcare names, reflecting market interest in this regulatory progress.
AEON Biopharma Shares FDA Feedback on ABP-450 Biosimilar Plan. AEON Biopharma received feedback from the FDA following a Type 2b meeting, which helps clarify the development path for its ABP-450 biosimilar candidate. This regulatory update provides specific guidance on the next steps for the company's pipeline. The stock recently appeared on lists of active healthcare names, reflecting market interest in this regulatory progress.